Peptidi

Human Thyroglobulin is a glycosylated, polypeptide chain having a total molecular mass of 660 kDa.  For solubility use phosphate buffer, pH>7.0 containing 0.15M NaCl.

A synthetic peptide for use as a blocking control in assays to test for specificity of KIAA0284 antibody, catalog no. 70R-3488

A synthetic peptide for use as a blocking control in assays to test for specificity of SCARB2 antibody, catalog no. 70R-10351

A synthetic peptide for use as a blocking control in assays to test for specificity of TFPI2 antibody, catalog no. 70R-5383

A synthetic peptide for use as a blocking control in assays to test for specificity of C13orf31 antibody, catalog no. 70R-4182

A synthetic peptide for use as a blocking control in assays to test for specificity of ST8SIA2 antibody, catalog no. 70R-7133

(Arg)9 is an cell-penetrating peptide made up of 9 arginine residues capable of traversing plasma membranes. It has been shown that Arg9 destabilize and disrupt the phospholipid bilayer allowing flow of ions across the membrane. (Arg)9 peptide plays an important role in efficient cellular uptake. The guanidinium group is a critical structural determinant for tight and rapid interactions with cell membrane. The cationic guanidinium group can form electrostatic interactions with anionic cell membranes components such as phospholipids and sulphated proteoglycans. This interaction can trigger the activation of specific intracellular signalling and cell internalization via various pathways. (Arg)9 peptide is used to deliver a variety of functionally active cargos such as peptides, small interfering RNA, oligonucleotides, plasmid DNA and liposomes into mammalian cells and plant cells with high translocation efficiency. (Arg)9 peptide can also be used to form chemical linkages with the cargo and act as a carrier peptide.

A synthetic peptide for use as a blocking control in assays to test for specificity of HSF1 antibody, catalog no. 20R-1123

A synthetic peptide for use as a blocking control in assays to test for specificity of FLCN antibody, catalog no. 70R-10331

The coronavirus (CoV) nucleoprotein is the major component of CoV structural proteins. Also known as the nucleocapsid protein, it is an abundant RNA-binding protein critical for viral genome packaging. These factors make nucleoprotein a good target for developing new antiviral drugs. In addition, the identification of epitopes within the nucleoprotein sequence can help design more effective SARS-CoV-2 vaccines.Models have predicted epitopes exhibiting antigenicity, stability and interactions with MHC class-I and class-II molecules. Nucleoprotein (351-365) is an epitope candidate with various HLA restrictions. This epitope can be used to better vaccine design for more durable CD4+ and CD8+ T cell responses for long-lasting immunity.

Alyerserin-2a is a C-terminally α-amidated 17 residue cationic anti-microbial peptide (AMP). Anti-microbial peptides (AMPs) are produced by the innate immune system and are expressed when the host is challenged by a pathogen. The Alyerserin family of peptides was first identified in norepinephrine-stimulated skin secretions of the midwife toad-Alytes obstetricans-(Alytidae). Alyteserin-2a, 2b and -2c show some sequence identity with bombinin H6, a peptide from the skins Bombinatoridae family of frogs.Alyteserin-2a is most potent against the Gram-positive bacteria-Staphylococcus aureus and has weak haemolytic activity against human erythrocytes.Alyteserin contain at least 50% hydrophobic amino acids. Hydrophobic residues contribute to the insertion of the peptide into the hydrophobic membrane core which results in membrane disruption and death of the pathogen. Due to their mechanism of action it is thought to be less likely for resistance to develop towards them compared to conventional antibiotics. Alyteserin-2a has the tendency to adopt an α-helical conformation between residues 9-14 when in membrane-mimetic solvent.

SARS-CoV-2 NSP7 (51-65)

Myelin oligodendrocyte glycoprotein (MOG) is a member of the immunoglobulin (Ig) protein superfamily and is expressed exclusively in the central nervous system (CNS) on the surface of myelin sheaths and oligodendrocyte processes. MOG is expressed at the onset of myelination, and therefore is a potential marker for oligodendrocyte maturation.MOG contains an extracellular domain, a transmembrane domain, a cytoplasmic loop, a membrane-associated region and a cytoplasmic tail. MOG may function as a cell surface receptor or cell adhesion molecule. -Fifteen different alternatively spliced isoforms have been detected in humans. These are present either on the cell surface, the endoplasmic reticulum in the endocytic system, or in secreted form.The secreted form of MOG may trigger autoimmunity if released into the cerebrospinal fluid and periphery. MOG is thought to be a key target for autoantibodies and cell-mediated immune responses in inflammatory demyelinating diseases such as multiple sclerosis (MS) and is therefore widely studied in this field.Fragment (35-51) of the human MOG can be rapidly degraded by the serine protease CatG. Conversion of arginine 46 to citrulline in this peptide reduces the sensitivity of the citrullinated MOG 35-51 peptide to degradation. This peptide has an uncharged C-terminal amide.

gp100 (280-288) A288V HLA-A*0201 antigen peptide – YLEPGPVTV

A synthetic peptide for use as a blocking control in assays to test for specificity of PCDH17 antibody, catalog no. 70R-2580

A synthetic peptide for use as a blocking control in assays to test for specificity of SCG3 antibody, catalog no. 70R-9777

Light chain of the bevacizumab monoclonal antibody, sold as the antitumour therapeutic Avastin. It prevents vascular endothelial growth factor (VEGF) from binding to VEGF receptors 1 and 2 thus inhibiting angiogenesis in tumours.

MAGE-A1 protein:
MAGE-A1 (278-286) is an epitope of Melanoma Antigen Gene A1 expressed by tumors of different histological types such as on the surface of breast carcinoma cell and is a Cancer/Testis Antigens (CTA). MAGE-A1 is a tumor antigen expressed in 40% of melanoma and contains epitope for binding HLA-A*02:01 molecules and that are recognized by cytotoxic T cells.
Applications of MAGE-A1 (278-286):
MAGE-A1 (278-286) is used to stimulate specific cytotoxic T cells in PBMCs and to analyze by ELISPOT peptide epitope specificity and cytokine production like IFN-γ. Immunogenicity of MAGE-A1 (278-286) raised the possibility of developing anticancer immunotherapies or vaccinations. MAGE-A1 is also expressed in lung adenocarcinoma and studies suggest that MAGE-A1 may serve to develop Chimeric Antigen Receptor (CAR) T cell therapy using lentiviral vector and show an encouraging tumor-inhibitory efficacy.

A synthetic peptide for use as a blocking control in assays to test for specificity of SP1 antibody, catalog no. 20R-1139

A synthetic peptide for use as a blocking control in assays to test for specificity of RNF148 antibody, catalog no. 70R-6421

A synthetic peptide for use as a blocking control in assays to test for specificity of POMT1 antibody, catalog no. 70R-6979

The coronavirus (CoV) nucleoprotein is the major component of CoV structural proteins. The nucleoprotein has a critical role in virus assembly and RNA transcription. The nucleoprotein is essential in the formation of helical ribonucleoproteins and in regulating viral RNA synthesis. The nucleoprotein can also regulate infected host cellular mechanisms. It is highly expressed during infection and may induce protective immune responses against SARS-CoV and SARS-CoV-2.The nucleoprotein residues HIDAYKTFPPTEPKK (356-370) from SARS-CoV-2 have been identified as a T-cell epitope with a predicted HLA restriction. Immune targeting of confirmed epitopes may potentially offer protection against SARS-CoV-2 and help the development of vaccines for long-lasting immunity.

A synthetic peptide for use as a blocking control in assays to test for specificity of C13ORF8 antibody, catalog no. 20R-1070

A synthetic peptide for use as a blocking control in assays to test for specificity of RBM42 antibody, catalog no. 70R-4934

A synthetic peptide for use as a blocking control in assays to test for specificity of SLC35A3 antibody, catalog no. 70R-7368

A synthetic peptide for use as a blocking control in assays to test for specificity of DES antibody, catalog no. 70R-1238

A synthetic peptide for use as a blocking control in assays to test for specificity of PRKAA2 antibody, catalog no. 70R-3231

A synthetic peptide for use as a blocking control in assays to test for specificity of STAU1 antibody, catalog no. 70R-5010

A synthetic peptide for use as a blocking control in assays to test for specificity of KCNH3 antibody, catalog no. 70R-8070

A synthetic peptide for use as a blocking control in assays to test for specificity of GP6 antibody, catalog no. 70R-7316

A synthetic peptide for use as a blocking control in assays to test for specificity of C16orf71 antibody, catalog no. 70R-9196

A synthetic peptide for use as a blocking control in assays to test for specificity of ZHX3 antibody, catalog no. 70R-9570

A synthetic peptide for use as a blocking control in assays to test for specificity of Ighmbp2 antibody, catalog no. 70R-8242

A synthetic peptide for use as a blocking control in assays to test for specificity of PIK3R5 antibody, catalog no. 70R-9300

A synthetic peptide for use as a blocking control in assays to test for specificity of PI4K2B antibody, catalog no. 70R-3490

A synthetic peptide for use as a blocking control in assays to test for specificity of KCNMB3 antibody, catalog no. 70R-5170

A synthetic peptide for use as a blocking control in assays to test for specificity of MAS1 antibody, catalog no. 70R-1838

Haemagglutinin (HA) peptide YPYDVPDYA – HA Tag

A synthetic peptide for use as a blocking control in assays to test for specificity of KCTD21 antibody, catalog no. 70R-3786

A synthetic peptide for use as a blocking control in assays to test for specificity of TMEM38A antibody, catalog no. 70R-6906

A synthetic peptide for use as a blocking control in assays to test for specificity of SNRK antibody, catalog no. 70R-2565

Cytochrome B5 Reductase 3, human, recombinant is a high-quality protein used in research and scientific studies. Produced using Escherichia Coli, this protein is essential for various biological processes. Cytochrome B5 Reductase 3 plays a crucial role in electron transfer reactions and is involved in the metabolism of drugs and toxins. It has been extensively studied for its ability to catalyze the reduction of cytochrome b5, an important component of the electron transport chain. This recombinant protein provides researchers with a reliable tool to investigate cellular processes and advance scientific knowledge.

A synthetic peptide for use as a blocking control in assays to test for specificity of FMO3 antibody, catalog no. 70R-6581

A synthetic peptide for use as a blocking control in assays to test for specificity of EXOC4 antibody, catalog no. 70R-2859

A synthetic peptide for use as a blocking control in assays to test for specificity of CHMP4A antibody, catalog no. 70R-10404

A synthetic peptide for use as a blocking control in assays to test for specificity of Ghitm antibody, catalog no. 70R-8666

A synthetic peptide for use as a blocking control in assays to test for specificity of PBLD antibody, catalog no. 70R-4307

Autoinducing peptide (AIPs) are produced by Staphylococcus aureus bacterium in order to regulate virulence.

A synthetic peptide for use as a blocking control in assays to test for specificity of GRK4 antibody, catalog no. 70R-3123